GRAIL Inc. (GRAL) vs Rhythm Pharmaceuticals, Inc. (RYTM)
A side-by-side comparison of GRAIL Inc. and Rhythm Pharmaceuticals, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
GRAL
GRAIL Inc.
$137.56HealthcareDelayed quote: Oct 6, 2026, 3:35 PM EDT
RYTM
Rhythm Pharmaceuticals, Inc.
$90.35HealthcareDelayed quote: Oct 6, 2026, 3:30 PM EDT
Total return — GRAL vs RYTM
growth of $100 · dividends reinvested · last 2yGRAL +1028.0% (+235.9%/yr)RYTM +130.4% (+51.8%/yr)GRAL compounded faster over this window
GRAL RYTM
GRAL vs RYTM: by the numbers
- •RYTM is the larger company ($6.20B vs $5.90B market cap).
- •Both run net losses; RYTM's is the smaller (-85.59% vs -236.95% net margin).
Metrics side by side
Valuation
| Metric | GRAL | RYTM |
|---|---|---|
| P/S ratio | 35.72 | 25.83 |
| P/B ratio | 2.32 | 60.18 |
Profitability
| Metric | GRAL | RYTM |
|---|---|---|
| Gross margin | -42.52% | 89.00% |
| Operating margin | -362.95% | -101.19% |
| Net margin | -236.95% | -85.59% |
| ROE | -15.40% | -94.50% |
| ROIC | -20.26% | -63.96% |
Growth (annualized)
| Metric | GRAL | RYTM |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 278.53% |
| Total return CAGR (5Y) | N/A | 49.95% |
Go deeper
Dig into the metrics
GRAIL ROERhythm Pharmaceuticals ROEGRAIL operating marginRhythm Pharmaceuticals operating marginGRAIL revenue growthRhythm Pharmaceuticals revenue growthGRAIL free cash flowRhythm Pharmaceuticals free cash flow
GRAIL & Rhythm Pharmaceuticals appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.